Anti-Aβ antibody target engagement

a response to Siemers et al

Andrew D Watt, Gabriela A N Crespi, Russell A Down, David B Ascher, Adam Gunn, Keyla A Perez, Catriona A McLean, Victor L Villemagne, Michael W Parker, Kevin J Barnham, Luke A Miles

Research output: Contribution to journalComment/debate

1 Citation (Scopus)

Abstract

We have read with interest the commentary by Siemers et al. [28] regarding our paper describing the ability of the three anti-Aβ antibodies, bapineuzumab, crenezumab and solanezumab to engage Aβ in both a synthetic and a biological setting. We appreciate the opportunity to clarify any misunderstandings and here provide a brief response to their concerns.
Original languageEnglish
Pages (from-to)611-4
Number of pages4
JournalActa Neuropathologica
Volume128
Issue number4
DOIs
Publication statusPublished - 2014
Externally publishedYes

Fingerprint

solanezumab
Anti-Idiotypic Antibodies
crenezumab
bapineuzumab

Cite this

Watt, A. D., Crespi, G. A. N., Down, R. A., Ascher, D. B., Gunn, A., Perez, K. A., ... Miles, L. A. (2014). Anti-Aβ antibody target engagement: a response to Siemers et al. Acta Neuropathologica, 128(4), 611-4. https://doi.org/10.1007/s00401-014-1333-8
Watt, Andrew D ; Crespi, Gabriela A N ; Down, Russell A ; Ascher, David B ; Gunn, Adam ; Perez, Keyla A ; McLean, Catriona A ; Villemagne, Victor L ; Parker, Michael W ; Barnham, Kevin J ; Miles, Luke A. / Anti-Aβ antibody target engagement : a response to Siemers et al. In: Acta Neuropathologica. 2014 ; Vol. 128, No. 4. pp. 611-4.
@article{ac66d783db374259a4b5c53f4c5a42dd,
title = "Anti-Aβ antibody target engagement: a response to Siemers et al",
abstract = "We have read with interest the commentary by Siemers et al. [28] regarding our paper describing the ability of the three anti-Aβ antibodies, bapineuzumab, crenezumab and solanezumab to engage Aβ in both a synthetic and a biological setting. We appreciate the opportunity to clarify any misunderstandings and here provide a brief response to their concerns.",
keywords = "Alzheimer Disease/drug therapy, Amyloid beta-Peptides/metabolism, Animals, Antibodies/metabolism, Female, Humans, Nootropic Agents/pharmacology",
author = "Watt, {Andrew D} and Crespi, {Gabriela A N} and Down, {Russell A} and Ascher, {David B} and Adam Gunn and Perez, {Keyla A} and McLean, {Catriona A} and Villemagne, {Victor L} and Parker, {Michael W} and Barnham, {Kevin J} and Miles, {Luke A}",
year = "2014",
doi = "10.1007/s00401-014-1333-8",
language = "English",
volume = "128",
pages = "611--4",
journal = "Acta Neuropathologica",
issn = "0001-6322",
publisher = "Springer Verlag",
number = "4",

}

Watt, AD, Crespi, GAN, Down, RA, Ascher, DB, Gunn, A, Perez, KA, McLean, CA, Villemagne, VL, Parker, MW, Barnham, KJ & Miles, LA 2014, 'Anti-Aβ antibody target engagement: a response to Siemers et al', Acta Neuropathologica, vol. 128, no. 4, pp. 611-4. https://doi.org/10.1007/s00401-014-1333-8

Anti-Aβ antibody target engagement : a response to Siemers et al. / Watt, Andrew D; Crespi, Gabriela A N; Down, Russell A; Ascher, David B; Gunn, Adam; Perez, Keyla A; McLean, Catriona A; Villemagne, Victor L; Parker, Michael W; Barnham, Kevin J; Miles, Luke A.

In: Acta Neuropathologica, Vol. 128, No. 4, 2014, p. 611-4.

Research output: Contribution to journalComment/debate

TY - JOUR

T1 - Anti-Aβ antibody target engagement

T2 - a response to Siemers et al

AU - Watt, Andrew D

AU - Crespi, Gabriela A N

AU - Down, Russell A

AU - Ascher, David B

AU - Gunn, Adam

AU - Perez, Keyla A

AU - McLean, Catriona A

AU - Villemagne, Victor L

AU - Parker, Michael W

AU - Barnham, Kevin J

AU - Miles, Luke A

PY - 2014

Y1 - 2014

N2 - We have read with interest the commentary by Siemers et al. [28] regarding our paper describing the ability of the three anti-Aβ antibodies, bapineuzumab, crenezumab and solanezumab to engage Aβ in both a synthetic and a biological setting. We appreciate the opportunity to clarify any misunderstandings and here provide a brief response to their concerns.

AB - We have read with interest the commentary by Siemers et al. [28] regarding our paper describing the ability of the three anti-Aβ antibodies, bapineuzumab, crenezumab and solanezumab to engage Aβ in both a synthetic and a biological setting. We appreciate the opportunity to clarify any misunderstandings and here provide a brief response to their concerns.

KW - Alzheimer Disease/drug therapy

KW - Amyloid beta-Peptides/metabolism

KW - Animals

KW - Antibodies/metabolism

KW - Female

KW - Humans

KW - Nootropic Agents/pharmacology

U2 - 10.1007/s00401-014-1333-8

DO - 10.1007/s00401-014-1333-8

M3 - Comment/debate

VL - 128

SP - 611

EP - 614

JO - Acta Neuropathologica

JF - Acta Neuropathologica

SN - 0001-6322

IS - 4

ER -

Watt AD, Crespi GAN, Down RA, Ascher DB, Gunn A, Perez KA et al. Anti-Aβ antibody target engagement: a response to Siemers et al. Acta Neuropathologica. 2014;128(4):611-4. https://doi.org/10.1007/s00401-014-1333-8